Oculis Holding AG

OCS Healthcare Biotechnology

Oculis Holding AG’s revenue for fiscal 2025 (year ended December 2025) was $1.4 million, up 85.7% from fiscal 2024.

Revenue
−97.2%
EPS
+9.20%
Free cash flow
−20.9%
Total debt
−4.44%

Quarter to September 2026, against a year earlier

7.49 0.66 +9.66%
Market cap
$421.6M
P/E
0.0×
Fwd P/E
−4.4×
Dividend yield
—
F-score
4/9
Altman Z
10.51
Beneish M
n/a
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
720.95 1,121.34 577.09 490.29
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(57.88) (80.03) (33.41) (26.08)
P/B ratio
4.41 6.24 3.06 2.25
EV/Sales
545.04 920.42 382.70 272.79
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(9.65) (16.04) (6.82) (3.71)
Current Ratio
5.96 5.18 8.35 10.41
Net Debt/EBITDA
9.94 10.21 9.68 8.91
Debt/Equity
0.01 0.01 0.01 0.01
Earnings Yield
(11.55%) (8.15%) (12.81%) (18.63%)
Free Cash Flow Yield
(7.83%) (5.12%) (9.73%) (14.99%)
Free Cash Flow per Share
(0.34) (0.33) (0.42) (0.36)
Book value per Share
4.53 4.26 4.53 4.16
Free Cash Flow
(18.01) (19.58) (25.45) (22.14)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026